Biosciences
Offspring
Profiling Therapeutic Antibody Binding Properties in Human Tissues
Accelerate Your Therapeutic Antibody Development with Precision Profiling
The Critical Gap in Therapeutic Antibody Development
The development of successful therapeutic antibodies requires precise understanding of their binding characteristics within physiologically relevant contexts. Traditional development approaches rely heavily on recombinant systems and cell-based assays that fail to recapitulate the complexity of human tissues. Therapeutic efficacy depends on binding within complex tissue microenvironments where epitope accessibility, target conformation, and spatial distribution differ substantially from simplified systems. This methodological disconnect contributes significantly to the translation gap between promising preclinical candidates and clinical outcomes.
​
Aβ with TAU
Bridging the Translational Gap: Our Tissue-Based Analytical Platform
Our tissue-based analytical approach bridges this translational gap by evaluating antibody binding properties directly in human tissues—both normal and disease-affected—providing physiologically relevant data on target engagement, off-target binding, and biomarker modulation. This approach aligns with industry frameworks such as AstraZeneca's 5R principles and Pfizer's Three Pillars concept, which emphasize the importance of validating target engagement within relevant human tissues to enhance clinical success rates.
Our Tissue-Based Analytical Platform
-
Single and multiplexed IHC/IF: For high-resolution binding visualization in context of biomarkers cell phenotype, disease pathology and anatomical landmarks.
-
In Situ Proximity Ligation Assay (isPLA): For sensitive and specific detection of protein interactions, including target engagement.
-
AI-Powered Quantitative Image Analysis: To provide robust, reproducible data.
-
High-Quality Human Tissue Microarrays (TMAs): For efficient, high-throughput screening and sparing of valuable human tissue
Case Study: Supporting the Development and Launch of Leqembi (lecanemab)
Offspring Biosciences has provided extensive support for the development of Leqembi — a novel antibody therapy for Alzheimer’s disease from BioArctic in collaboration with Eisai and Biogen — by delivering tissue-based, quantitative characterization of antibody binding to various forms of amyloid‑beta deposits in Alzheimer’s brain samples and demonstrating competitive differentiation versus other anti‑amyloid antibodies.
A Tiered Service Model to Overcome Key Development Hurdles
-
Hit and Lead Identification
-
Early-stage antibody selection presents significant challenges due to limited material and the need to rapidly screen numerous candidates. Our hit and lead identification service streamlines this process through efficient, tissue-based screening. We evaluate dozens of candidate antibodies on focused sets of human tissues using standardized IHC protocols to provide rapid, cost-effective decision support. Promising leads can then undergo more detailed characterization on expanded tissue panels, allowing you to select candidates with optimal binding properties that might be missed by conventional screening methods.
-
Lead Optimization
-
Optimizing antibody candidates for clinical success requires a deep understanding of their binding properties in physiologically relevant contexts. Our lead optimization services provide this through detailed characterization of your top 1-3 candidates on comprehensive human tissue panels. We guide engineering efforts by assessing affinity and specificity, performing competitive benchmarking against clinical-stage antibodies, and conducting mechanistic studies to evaluate epitope accessibility. These critical insights predict in vivo performance more accurately than conventional methods, strengthening your candidate's developability profile and intellectual property claims.
-
Preclinical and Clinical Development Support
-
As your candidate antibody progresses towards the clinic, our services provide the critical data needed for successful IND-enabling studies and beyond. We support comprehensive tissue cross-reactivity (TCR) screening to identify potential off-target binding, evaluate species cross reactivity to ensure appropriate animal model selection and antibody distribution and demonstation of target engagement after in vivo administration. For clinical trials, we bridge preclinical findings to human outcomes by characterizing antibody binding profiles in cohorts of patient tissues as support to patient stratification. This integrated approach provides a robust, regulatory-ready data package that mitigates risk and maximizes the likelihood of success in the clinic.
Our analytical services delivers integrated, tissue-based antibody binding profiling that provides physiologically relevant evidence to de-risk decisions, strengthen target engagement claims, and sharpen competitive differentiation. Our tiered model combines molecular pathology expertise, proprietary human tissue resources, and advanced analytics to accelerate development, reduce costs, and improve the odds of clinical success. Contact us to discuss tailored solutions for your current programs and specific development challenges.